TechnoPharm / POWTECH 2014 Nuremberg, Germany

GEA spoke to Biopharma-Reporter at the Nuremberg Conference Centre yesterday

DISPATCHES FOM TECHNOPHARM, NUREMBERG

MAb production driving continuous fermentation, says GEA

By Dan Stanton

Development of continuous fermentation has been driven by the increased production of monoclonal antibodies says GEA, with Asia-Pacific the new growth driver for such technologies.